CBS 2019
CBSMD教育中心
中 文

Pulmonary Hypertension

Abstract

Recommended Article

Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry Genetic analyses in a cohort of 191 pulmonary arterial hypertension patients The right ventricle in pulmonary hypertension Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension Risk Stratification in PAH Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension Definition and Management of Segmental Pulmonary Hypertension

Clinical Trial 2001 Jan 2;103(1):10-3.

JOURNAL:Circulation. Article Link

Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension

Feinstein JA, Goldhaber SZ, Lock JE et al. Keywords: Balloon pulmonary angioplasty; chronic thromboembolic pulmonary hypertension

Abstract


BACKGROUNDAlthough pulmonary thromboendarterectomy is increasingly successful for the definitive treatment of chronicthromboembolic pulmonary hypertension (CTEPH), not all patients have surgically accessible disease. Others are poor surgical candidates because of comorbid illness. Therefore, for selected patients, we defined and implemented an alternative interventional strategy of balloon pulmonary angioplasty (BPA).

METHODS AND RESULTSEighteen patients (mean age, 51.8 years; range, 14 to 75 years) with CTEPH underwent BPA; they averaged 2.6 procedures (range, 1 to 5) and 6 dilations (range, 1 to 12). Selection of pulmonary artery segments for dilation required (1) complete occlusion, (2) filling defects, or (3) signs of intravascular webs. After an average of 36 months of follow-up (range, 0.5 to 66 months), the average New York Heart Association class improved from 3.3 to 1.8 (P:<0.001), and 6-minute walking distances increased from 209 to 497 yards (P:<0.0001). Pulmonary artery mean pressures decreased from 43.0+/-12.1 to 33. 7+/-10.2 mm Hg (P:=0.007). Eleven patients developed reperfusion pulmonary edema; 3 required mechanical ventilation.

CONCLUSIONSBPA reduces pulmonary artery hypertension in patients with CTEPH and is associated with long-term improvement in New York Heart Association class and 6-minute walking distances. BPA is a promising interventional technique that warrants randomized comparison with medical therapy in CTEPH patients who are not surgical candidates.